Advances and challenges for drug interaction evaluation - Perspectives on the IC...

연구 요약

Advances and challenges for drug interaction evaluation - Perspectives on the ICH M12 guideline.

Drug metabolism and pharmacokinetics 학술지에 발표된 이 연구는 Yang X, Versantvoort C, Hoshino M 외 연구팀이 수행하였습니다.

이 연구는 'Advances and challenges for drug interaction evaluation - Perspectives on the ICH M12 guideline.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Drug-drug interaction (DDI) is an important factor to consider when determining the drug and optimal dose for individual patients. The DDI potential of an investigational drug is routinely evaluated during development. For pharmacokinetics-based DDIs, regional regulatory guidelines were developed providing recommendations on in vitro and clinical DDI evaluations. Recently, a globally harmonized DDI (M12) guideline was issued by the International Council for Harmonization (ICH) and adopted by regulatory agencies worldwide. The M12 guideline describes a stepwise, risk-based approach that leverages in vitro and clinical data and is facilitated by modeling tools and endogenous biomarker information. Compared to regional guidelines, several aspects were expanded or updated in the M12 guideline, including the utility of endogenous biomarkers and revisions of in vitro-to-in vivo extrapolation (IVIVE) criteria to predict the in vivo potential of CYP inhibition or induction. In this review, we provided the current status of M12 guideline implementation in the EU, Japan, and the US, clarified the scope of the guideline, described the application of biomarkers of transporters or enzymes in regulatory submissions and reviews, shared the rationale underlying the modifications of certain IVIVE criteria, and discussed some remaining challenges that need collaborative effort from academia, industry, and regulators to address.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41812533)